Session 5 – A New Paradigm in Biotech Innovation & Investment
Date: 22 July (Wednesday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Michael Huang joined Taiwania Capital Management Corporation as Managing Partner of Life Science Investments in 2018.
Prior to joining Taiwania, Michael was the Co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the field of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed licensing deals with Sihuan Pharmaceutical and Sanofi Korea. Prior to NPV Asia, he had served as head of IR for TWi Pharmaceuticals, Inc., a specialty generics company in Taiwan, and had played a critical role during TWi's IPO process.
Before working in the industry, Michael had over 12 years of experience as venture capitalist, focusing on investments in life science startups in US, Taiwan and Japan. Some of his notable deals include Coley Pharmaceuticals, Inc. (Nasdaq Listed then acquired by Pfizer), MediciNova (Dual listing on Nasdaq and Osaka Stock Exchange), Nellix, Inc. (acquired by Endologix), Mycenax Biotech, Inc. (TPEx), Savior Lifetec Corp. (TPEx), PharmaEngine, Inc. (TPEx), Apex International Co. (Acquired by Paraxel). Michael currently serves on the board of Annji Pharma, Elixiron Biotherapeutics, Fractyl Laboratories, Frequency Therapeutics (FREQ), Point Robotics, Regenacy Pharmaceuticals , and Viracta Therapeutics.
His expertise is in investing and managing early to late stage biotech and medical device companies in the Greater China, Japan, European and North America regions. He has proven track record in investment return, project management, operation management, business planning and financial planning.
Speech title & Synopsis
In the era of globalization, Asia has gradually increasing its role and importance for product development. With its geographical location and competitive advantage in human resources, Taiwan can serve as a gateway for biotech and medtech companies to Asia. In this session, we will discuss how can Taiwan can establish itself as the regional hub for biotech developments within and beyond Asian territory, very much like the airlines’ hub-and-spoke system.